Boulder-based biotech company Enveda has raised $150 million in a Series D funding round and appointed former Pfizer Chief Scientific Officer Dr. Mikael Dolsten to its board of directors.
According to a company news release, the financing round was led by Premji Invest, with participation from Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures and others. This follows Enveda’s $150 million Series C in February, bringing its total funding to $517 million.
Enveda uses an AI-driven platform to analyze the chemical diversity found in nature and discover new medicines. The latest funding will help advance several clinical programs into Phase 1b and Phase 2 trials and support Investigational New Drug, or IND, applications in the coming months.
Dolsten brings decades of experience in advancing scientific discoveries from research through commercialization and is expected to play a key role in guiding Enveda’s continued development.
